Publications and Resources

Publications

Human Papillomavirus 16/18–Associated Cervical Lesions: Differences by Area-Based Measures of Race and Poverty. Brackney MM, Gargano JW, Hannagan SE, Meek J, Querec TD, Niccolai LM. Am J Prev Med. 2020;58(5): e149-e157. doi: 10.1016/j.amepre.2019.12.003. Epub 2020 Jan 28.

Effectiveness of 1, 2, and 3 Human Papillomavirus Vaccine doses against HPV-16/18 positive High-grade Cervical Lesions. Johnson Jones ML, Gargano JW, Powell M, Park IU, Niccolai LM, Bennett NM, Griffin MR, Querec T, Unger ER, Markowitz LE; HPV-IMPACT Working Group. Am J Epidemiol. 2019 Nov 4. pii: kwz253. doi: 10.1093/aje/kwz253. [Epub ahead of print]
Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States. Saadeh K, Park I, Gargano JW, Whitney E, Querec TD, Hurley L, Silverberg M. Vaccine. 2019 Oct 11. pii: S0264-410X(19)31347-7. doi: 10.1016/j.vaccine.2019.09.103. [Epub ahead of print]
Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women – United States, 2008 and 2016. McClung NM, Gargano JW, Park IU, Whitney E, Abdullah N, Ehlers S, Bennett NM, Scahill M, Niccolai LM, Brackney M, Griffin MR, Pemmaraju M, Querec TD, Cleveland AA, Unger ER, Markowitz LE; HPV-IMPACT Working Group. MMWR.2019 ;68(15):337-343.
Trends in Human Papillomavirus Types 16 and 18 in Cervical Precancers, 2008-2014. McClung NM, Gargano JW, Bennett NM, Niccolai LM, Abdullah N, Griffin MR, Park IU, Cleveland AA, Querec T, Unger ER, Markowitz LE, HPV-IMPACT Working Group. Cancer Epidemiology, Biomarkers, and Prevention, 2019;28(3):602-609.
Trends in High-grade Cervical Lesions and Cervical Cancer Screening in Five States, 2008–2015. Gargano J, Park IU, Griffin MR et al. Clin Infect Dis 2019;68(8):1282-91.
Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015. Cleveland AA, Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, Bennett NM, Saadeh K, Pemmaraju M, Higgins K, Ehlers S, Scahill M, Johnson Jones ML, Querec T, Markowitz LE, Unger ER; HPV-IMPACT Working Group. Int J Cancer. 2019 Apr 13. doi: 10.1002/ijc.32340. [Epub ahead of print]

Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era. Oakley F, Desouki MM, Pemmaraju M, Gargano JM, Markowitz LE, Steinau M, Unger ER, Zhu Y, Fadare O, Griffin; Am J Prev Med. 2018 Jul;55(1):19-25. doi: 10.1016/j.amepre.2018.03.015. Epub 2018 May 16.

Use of claims data to estimate annual cervical cancer screening percentages in Portland metropolitan area, Oregon. Abdullah N, Laing RS, Hariri S, Young CM, Schafer S. Cancer Epidemiol. 2016 Apr;41:106-12. doi: 10.1016/j.canep.2016.01.010. Epub 2016 Feb 18.

Monitoring effect of human papillomavirus vaccines in US population, Emerging Infections Program, 2008-2012. Hariri S, Markowitz LE, Bennett NM, Niccolai LM, Schafer S, Bloch K, Park IU, Scahill MW, Julian P, Abdullah N, Levine D, Whitney E, Unger ER, Steinau M, Bauer HM, Meek J, Hadler J, Sosa L, Powell SE, Johnson ML; HPV-IMPACT Working Group. Emerg Infect Dis. 2015 Sep;21(9):1557-61.
Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Hariri S, Johnson ML, Bennett NM, Bauer HM, Park IU, Schafer S, Niccolai LM, Unger ER, Markowitz LE; HPV-IMPACT Working Group. Cancer. 2015 Aug 15;121(16):2775-81.
Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States – 2008-2012. Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, Unger ER, Whitney E, Julian P, Scahill MW, Abdullah N, Levine D, Johnson ML, Steinau M, Markowitz LE; HPV-IMPACT Working Group. Vaccine. 2015 Mar 24;33(13):1608-13.
HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States. Hariri S, Unger ER, Schafer S, Niccolai LM, Park IU, Bloch KC, Bennett NM, Steinau M, Johnson ML, Markowitz LE; HPV-IMPACT Working Group. Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):393-9.

Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty. Niccolai LM, Russ C, Julian PJ, Hariri S, Sinard J, Meek JI, McBride V, Markowitz LE, Unger ER, Hadler JL, Sosa LE. Cancer. 2013 Aug 15;119(16):3052-8. doi: 10.1002/cncr.28038. Epub 2013 May 9.

Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Powell SE, Hariri S, Steinau M, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Unger ER, Markowitz LE. Vaccine. 2012 Dec 17;31(1):109-13.
Human papillomavirus genotypes in high-grade cervical lesions in the United States. Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Steinau M, Markowitz LE; HPV-IMPACT Working Group. J Infect Dis. 2012 Dec 15;206(12):1878-86.
The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Markowitz LE; HPV-IMPACT Working Group. Cancer Causes Control. 2012 Feb;23(2):281-8.

Resources

For more information on work CDC is doing to help prevent and control HPV and monitor impact of HPV vaccine, please visit: